Fortress Biotech, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Fortress Biotech, Inc. (FBIO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $1.68 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-03-31
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.68.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.50.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2021-03-31 was $4.88.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2015-03-31 was $0.00, a 100.00% decline year-over-year.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $1.68.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $8.14, a 29.82% increase from fiscal 2022.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $6.27, a 44.80% increase from fiscal 2021.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2021 was $4.33, a 68.48% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.68 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $1.68 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $8.14 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $37.50 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $2.50 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $2.50 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $6.27 10-K · filed 2023-03-31 | |||
| 2021-12-31 | $4.33 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $4.33 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | $4.88 10-Q · filed 2021-08-16 | |||
| 2021-03-31 | $4.88 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | $2.57 10-K · filed 2022-03-28 | |||
| 2020-09-30 | $2.55 10-Q · filed 2020-11-09 | |||
| 2018-12-31 | $4.75 10-K · filed 2020-03-16 | |||
| 2017-12-31 | $4.75 10-K · filed 2019-03-18 | |||
| 2017-09-30 | $1.37 10-Q · filed 2017-11-09 | |||
| 2016-12-31 | $0.51 10-K · filed 2018-03-16 | |||
| 2016-09-30 | $0.51 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | $2.10 10-Q · filed 2016-08-09 | |||
| 2015-12-31 | $7.57 10-K · filed 2016-03-15 | |||
| 2015-09-30 | $7.57 10-Q · filed 2015-11-09 | |||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-10 | |||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $4.28 10-K · filed 2015-03-16 | |||
| 2014-09-30 | $4.28 10-Q · filed 2014-11-06 | |||
| 2014-06-30 | $4.28 10-Q · filed 2014-08-11 | |||
| 2014-03-31 | $4.39 10-Q · filed 2014-05-12 | |||
| 2013-12-31 | $5.51 10-K · filed 2014-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |